

Focelite develops Welblu to combat COVID-19 variants

14 January 2022 | News

The repurposed drug in an oral form is used in integration with a low visible light-emitting wrist band device



Bengaluru-based startup Focelite has developed Welblu, an innovative product to treat COVID-19, in collaboration with its US partner.

The repurposed drug in an oral form used in integration with a low visible light-emitting wrist band device is effective in disruption of the lipid bilayer of corona virus.

This lipid bilayer acts as a skeleton for spike protein structural support to mobilise virus into human cells. The emitted low wavelength light penetrates through the dermal capillary of skin and into the blood vessels, catalyses response rate against the invasion of virus inside the human body and enables the transformation of the drug into two forms.

The unique therapeutic action of Welblu can be a potential solution to combat different variants of the spike protein including the omicron (B.1.1.529) based its action on viral Lipid Bilayer.

The results of the clinical studies have provided encouraging results with patients showing significant recovery. RT-PCR tests conducted in the trial group resulted in a mean time of negative PCR in three days. No allergic reaction was seen in the clinical study group. A trial is now underway for paediatric use and with the promising result can bridge the gap of the non-vaccinated, paediatric group.